Polyrizon Director Oz Adler disposes of USD 0.0 million common shares

Polyrizon director Carmel Liron disposes of shares worth $0.0011 million

Polyrizon CEO Tomer Izraeli disposes of 3,900 shares worth $0.04 million

Polyrizon completes FDA pre-submission meeting for NASARIX; submits FDA Pre-RFD for PL-16 viral blocker

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon FY2025 operating loss widened 380% to $6.25 million; revenue was no revenue

Polyrizon signs MOU to buy up to 20% of Colugo for up to USD 6 million

Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced Evtol Drones for Defense and Urban Air Mobility Applications

Polyrizon Ltd. Director Liat Sidi Files Initial Beneficial Ownership Statement

Polyrizon Ltd. Chief Science Officer Eyal S. Ron filed initial beneficial ownership statement

Polyrizon Ltd. Director Yehonatan Zalman Vinokur Files Initial Beneficial Ownership Statement

Polyrizon Ltd. files Form 3 initial beneficial ownership statement for Director Carmel Liron

Polyrizon Ltd. files initial beneficial ownership statement for CTO Tidhar Turgeman

Polyrizon Ltd. director Oz Adler files initial beneficial ownership statement

Polyrizon Ltd. files Form 3 beneficial ownership statement for CEO Tomer Izraeli

Polyrizon Ltd. CFO Nir BenYosef files initial beneficial ownership statement

Polyrizon signs agreement with research organization for clinical development

Polyrizon signs agreement with global preclinical CRO for ISO 10993 biocompatibility studies

Polyrizon Signs an Agreement With Leading Global Preclinical Cro as Part of Clinical Development Program

Polyrizon Produces GMP Clinical Trial Material Batch With Eurofins CDMO AmatsiAquitaine